As IL-33 may be protective in human IBD, expanded studies correlating Sprouty2, IL-33, and colitis outcomes will be important to pursue to determine whether SPRY2 acts as a biomarker for disease severity. This evidence concerns the gene IL33 and inflammatory bowel disease.